Related Experiment Videos

Pharmacotherapy for MASLD: current evidence and challenges in clinical practice

Laura Pages1, Diego Rojo1, Alba Jimenez-Masip2

  • 1Liver Unit, Division of Digestive Diseases, Vall d'Hebron University Hospital, Barcelona, Spain; Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Annals of Hepatology
|October 23, 2026
PubMed

Keywords:
CSPH, clinically significant portal hypertensionDAMP, damage-associated molecular patternsDNL, de novo lipogenesisELF, enhanced liver fibrosisEMA, European Medicines AgencyFASN, fatty acid synthaseFDA, Food and Drug AdministrationFFA, free fatty acidsFGF21, fibroblast growth factor 21GCG, glucagonGIP, glucose-dependent insulinotropic peptideGIP/GLP-1, glucose-dependent insulinotropic peptide / glucagon-like peptide-1 receptor agonistGLP-1 RA, glucagon-like peptide-1 receptor agonistGLP-1, glucagon-like peptide-1GLP-1/GCG RA, glucagon-like peptide-1 / glucagon receptor agonistHDL, high density lipoproteinHbA1c, glycated haemoglobinLDL, low density lipoproteinLFC, liver fat contentLSM, liver stiffness measurementMACE, major adverse cardiovascular eventsMALO, major adverse liver outcomesMASH, metabolic dysfunction-associated steatohepatitisMASL, metabolic dysfunction-associated steatotic liverMASLD, metabolic dysfunction-associated steatotic liver diseaseMASLD, treatment, resmetirom, incretin agonists, non-invasive tests, Abbreviations: BMI, body mass indexMELD, model for end-stage liver diseaseMetALD, metabolic dysfunction-associated steatotic liver disease with increased alcohol consumptionNAS, nonalcoholic fatty liver disease activity scoreNIT, non-invasive testPAMP, pathogen-associated molecular patternsPPAR, peroxisome proliferator-activated receptorRCT, randomized controlled trialsSAF, steatosis-activity-fibrosis activitySGLT2i, sodium-glucose co-transporter-2 inhibitorsT2D, type 2 diabetes mellitusTHR-β, thyroid hormone receptor-βVAT, visceral adipose tissueVCTE, vibration-controlled transient elastography

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).